BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 16775032)

  • 21. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein.
    Kaelin WG
    Cancer; 2009 May; 115(10 Suppl):2262-72. PubMed ID: 19402056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2.
    Kurban G; Duplan E; Ramlal N; Hudon V; Sado Y; Ninomiya Y; Pause A
    Oncogene; 2008 Feb; 27(7):1004-12. PubMed ID: 17700531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance.
    Thoma CR; Frew IJ; Krek W
    Cell Cycle; 2007 Aug; 6(15):1809-13. PubMed ID: 17671433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
    Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
    Knauth K; Bex C; Jemth P; Buchberger A
    Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
    Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
    Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression pattern of the von Hippel-Lindau protein in human tissues.
    Los M; Jansen GH; Kaelin WG; Lips CJ; Blijham GH; Voest EE
    Lab Invest; 1996 Aug; 75(2):231-8. PubMed ID: 8765323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
    Huang YR; Zhang J; Wang JD; Fan XD
    Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression.
    Wiesener MS; Maxwell PH; Eckardt KU
    J Mol Med (Berl); 2009 Sep; 87(9):871-7. PubMed ID: 19629420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.